RxDoctor Payments Data

Manuel Reich, DO

Psychiatry · Monroeville, PANPI 1629093992

Payments from drug & device makers

$1,660in general payments, 2019–2025

Across 91 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$372
  • Otsuka America Pharmaceutical, Inc.$309
  • Johnson & Johnson$238
  • Orexo US, Inc.$217
  • Lundbeck LLC$91
  • Sunovion Pharmaceuticals Inc.$90
  • plus $343 from 12 others

What the payments were for

  • Food & beverage$1,660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,660 in reported general payments places this provider in the 80th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$13,734
Medicare patients
48
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate11$26,355
CymbaltaDuloxetine Hcl13$6,498
Bupropion XlBupropion Hcl103$5,427
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl19$3,822
Tranylcypromine Sulfate12$3,130
Clonazepam317$2,497
Aripiprazole85$2,174
Atomoxetine Hcl14$1,961
Trazodone Hcl147$1,869
Bupropion Hcl SrBupropion Hcl82$1,504
Desvenlafaxine Succinate ErDesvenlafaxine Succinate24$1,504
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine51$1,448
Duloxetine Hcl93$1,183
Escitalopram Oxalate63$1,168
Buspirone Hcl36$1,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$238$26,35511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Monroeville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →